Combination Therapy for Manic Phases: A Critical Review of a Common Practice

CNS Neuroscience and Therapeutics

Volumn 18, Issue 12, 2012, Pages 957-964

  Geoffroy, Pierre Alexis ^a,b,c,d   Etain, Bruno ^a,b,d,e   Henry, Chantal ^a,b,d,e   Bellivier, Frank ^a,b,d,e  

^a INSERM U955   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIV LILLE   (France)

^d FONDATION FONDAMENTAL   (France)

^e FACULTÉ DE MÉDECINE   (France)

Author keywords

Adjunction; Bipolar disorder; Combination; Mania; Monotherapy; Polytherapy; Safety; Side effects; Tolerability

Indexed keywords

ALLOPURINOL; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TAMOXIFEN; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; BIPOLAR DISORDER; BODY WEIGHT; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; MANIA; MEDLINE; METABOLIC SYNDROME X; MONOTHERAPY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANDOMIZED CONTROLLLED; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREMOR;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CHLORIDE; VALPROIC ACID;

EID: 84870415404     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12017     Document Type: Review

References (60)

1. Rosa AR, Franco C, Martínez-Aran A, et al. Functional impairment in patients with remitted bipolar disorder. Psychother Psychosom 2008;77:390-392.
2. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85-116.
3. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxford) 2009;23:346-388.
4. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225-255.
5. Malhi GS, Adams D, Lampe L, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009;439:27-46.
6. NICE. Bipolar disorder [Internet]. NICE. 2006 July 26;Available from: http://www.nice.org.uk/
7. Lim PZ, Tunis SL, Edell WS, Jensik SE, Tohen M. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord 2001;3:165-173.
8. Nivoli AMA, Murru A, Goikolea JM, et al. New treatment guidelines for acute bipolar mania: A critical review. J Affect Disord 2012;140:125-141.
9. Wolfsperger M, Greil W, Rössler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord 2007;99:9-17.
10. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
11. Haro JM, Reed C, Gonzalez-Pinto A, Novick D, Bertsch J, Vieta E. 2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery. Eur Neuropsychopharmacol 2011;21:287-293.
12. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl.):1-50.
13. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980;2:279-288.
14. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984;41:165-170.
15. Muller AA, Stoll KD. Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany. In: Emrich HM, Okuma T, Muller AA, editors. Anticonvulsants in Affective Disorders. Amsterdam, the Netherlands: Excerpta Medica, 1984:134-147.
16. Desai NG, Gangadhar BN, Channabasavanna SM, Shetty KT. Carbamazepine hastens therapeutic action of lithium in mania. Proceedings International Conference on New Directions in Affective Disorders. Jerusalem, Israel, 1987:97.
17. Möller HJ, Kissling W, Riehl T, Bäuml J, Binz U, Wendt G. Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:127-136.
18. Anand A, Oren DA, Berman RM, Cappiello A, Charney DS. Lamotrigine treatment of lithium failure outpatient mania: a double-blind, placebo-controlled trial. In: Scares JC, Gershon S, editors. Abstract Book on 3rd International Conference on Bipolar disorder. Pittsburgh, PA. Copenhagen: Munksgaard, 1999; 23
19. Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000;20:195-203.
20. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2:249-255.
21. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-1154.
22. Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-69.
23. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216-1223.
24. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003;182:141-147.
25. Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-223.
26. McIntyre RS, Konarski JZ, Jones M, Paulsson B. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J Affect Disord 2007;100(Suppl. 1):S5-S14.
27. Yatham LN, Vieta E, Young AH, Möller H-J, Paulsson B, Vågerö M. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol 2007;22:212-220.
28. Sussman N, Mullen J, Paulsson B, Vågerö M. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. J Affect Disord 2007;100(Suppl. 1):S55-S63.
29. Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008;165:1316-1325.
30. Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008;192:135-143.
31. Juruena MF, Ottoni GL, Machado-Vieira R, et al. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:94-99.
32. Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 2011;129:327-331.
33. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011;129:252-260.
34. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J. Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder: Results of a 12-Week Core Study and 40-Week Extension. J Clin Psychopharmacol 2012;32:46-55.
35. Ouyang W-C, Hsu M-C, Yeh I-N, Kuo C-C. Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. Int J Psychiatry Clin Pract 2012;16:178-188.
36. Cookson J. Use of antipsychotic drugs and lithium in mania. Br J Psychiatry 2001;178(Suppl. 41):S148-S156.
37. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:1306-1315.
38. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007;9:551-560.
39. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007;9:394-412.
40. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385-395.
41. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251-263.
42. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476-488.
43. Altamura AC, Mundo E, Dell'Osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. J Affect Disord 2008;110:135-141.
44. Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-345.
45. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130-137.
46. Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13:133-144.
47. Woo YS, Bahk W-M, Chung MY, et al. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. Hum Psychopharmacol 2011;26:543-553.
48. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010;26:1485-1496.
49. Carlson BX, Ketter TA, Sun W, et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012;14:41-53.
50. Zarate CA. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-171.
51. Vieta E, Cruz N, García-Campayo J, et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008;11:445-452.
52. Vieta E, Günther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-1049.
53. Geoffroy PA, Goddefroy G, Rolland B, Cottencin O. Efficacy of aripiprazole in comorbid addiction in bipolar disorder. CNS Neurosci Ther 2012;18:359-360.
54. Brown ES, Jeffress J, Liggin JDM, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005;66:756-760.
55. Geoffroy PA, Etain B, Scott J, et al. Clinical characteristics, biomarkers and therapeutic relevance of early-onset bipolar disorder. J Physiol Paris 2012; In press.
56. Ketter TA. Treating bipolar disorder: monotherapy versus combination therapy. J Clin Psychiatry 2009;70:e42.
57. Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008;69(Suppl. 5):9-15.
58. Berk M, Malhi GS. Should antipsychotics take pole position in mania treatment? Lancet 2011;378:1279-1281.
59. Kozicky J-M, Torres IJ, Bond DJ, Lam RW, Yatham LN. Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. Int Clin Psychopharmacol 2012;27:91-99.
60. Brooks JO 3rd, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry 2011;72:240-247.